5 completed, 1 recruiting. 2 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow Thomas Lund: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Self-administration of Subcutaneous Elranatamab in the Patients' Homes. Elranatamab - Multiple Myeloma | Phase 2 | Recruiting | Thomas Lund | 20 | 2025-01-29 | 2026-02-10 |
| Home Treatment With Carfilzomib in Patients With Multiple Myeloma Carfilzomib - Multiple Myeloma | Completed | Thomas Lund | 9 | 2022-12-15 | 2026-06-10 | |
| Daratumumab Provided at Home Experience An Open, Single-center, Mixed-method Project. Darzalex - Multiple Myeloma | Completed | Thomas Lund | 40 | 2022-04-01 | 2024-04-03 | |
| Anti-neoplastic Treatment, Based on PRO Data Reported Through a MHealth App Solution in Multiple Myeloma mHealth app - Multiple Myeloma | Completed | Thomas Lund | 33 | 2021-05-01 | 2023-02-21 | |
| Bone Healing During Ninlaro Exposure Ixazomib - Multiple Myeloma | Phase 2 | Completed | Thomas Lund | 30 | 2019-10-24 | 2024-04-03 |
| Prolonged Protection From Bone Disease in Multiple Myeloma Zoledronic acid - Multiple Myeloma | Phase 4 | Completed | Thomas Lund | 158 | 2015-01-01 | 2023-02-17 |
Multiple Myeloma (6) · Osteolysis (1) · Osteonecrosis (1)
Zoledronic Acid (1) · carfilzomib (1) · daratumumab (1) · ixazomib (1)
Denmark (6)
Jannie Kirkegaard, RN (1) · Karin Dieperink, RN, PhD (1) · Nana Hyldig, PhD, RN (1)
2014 (1)